A MULTICENTER OPEN-LABEL EXTENSION STUDY FOR SUBJECTS WHO PARTICIPATED IN STUDY B0151003 (ANDANTE II)
Phase of Trial: Phase II
Latest Information Update: 11 Jun 2019
At a glance
- Drugs PF 4236921 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Acronyms ANDANTE-II
- Sponsors Pfizer
- 26 May 2016 This trial was completed in Italy and Ireland (end date: 2016-03-01) and prematurely ended in Greece according to the European Clinical Trials Database
- 26 Apr 2016 This trial was completed in Belgium,Austria, Sweden and Czech Republic (end date: 2016-03-01), according to the European Clinical Trials Database.
- 25 Apr 2016 Status changed from active, no longer recruiting to completed.